Impact of a Community-Based Molecular Cancer Conference on Physician Practice and Clinical Care.

e18774 Background: Molecular tumor boards are useful for understanding molecular profiles and matching patients to targeted therapies. But, a scalable committee to review a high volume of patient reports and provide scientific guidance to oncologists affiliated with non-academic institutions does not yet exist. Sarah Cannon initiated a Molecular Cancer Conference (MCC) in May 2017 to review molecular results for Sarah Cannon’s community-based network of medical oncologists. Here, we report the results of a MCC pilot at a community oncology practice. Methods: The MCC reviews the next-generation sequencing results ordered by treating oncologists as a part of standard patient care. The committee met every two weeks to provide scientific guidance for targeted therapy selection, immunotherapy options, therapy contraindications, potential clinical trial options, and potential hereditary cancer syndrome implications based on molecular results. Results: Molecular profiling more than doubled (2.1 fold increase) since the initiation of the MCC (from 14 to 32 orders/month). Physicians participating in the MCC used more recent biopsies – instead of archival tissue – for molecular testing than those not participating in the MCC (64.3 and 128.9 days between biopsy and test, respectfully). Clinical trials were discussed for 218 cases, 35 patients enrolled on a clinical trial, and 4 patients were enrolled on two different clinical trials. Of those enrolled, 15 remain on study with either a partial response (2) or stable disease (13) with response times ranging from 1 month to 9 months. 17 patients have stopped clinical trial treatment due to progressive disease (response times between 1 and 6 months) and 2 patients stopped clinical trial treatment due to patient choice. Conclusions: Molecular profiles reviewed at the molecular conference committee lead to the suggestion of clinical trials 95.2% of the time. Physician education led to changes in the frequency, point in care, and utility of molecular profiles. These data demonstrate the need to study the clinical benefit of having scientific review of molecular profiles, and potentiate the need for physician education and training around the importance and utility of molecular profiling.